Last updated: February 25, 2026
What is the Drug Product?
NDC 00115-1751 is a prescribed formulation in the national drug code system. It is a branded drug marketed under the label Xeljanze (Xeljanz), approved for multiple autoimmune conditions, including rheumatoid arthritis and psoriatic arthritis.
Current Market Position
- Indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis.
- Formulation: Oral tablets with strengths of 5 mg and 10 mg.
- Authorized Uses: Shown effective in reducing symptoms and disease progression in targeted populations.
- Market Penetration: Estimated to hold roughly 20% of the prescription autoimmune therapy market in the U.S., making it a significant player among biologics and targeted synthetic DMARDs.
Competitive Landscape
| Competitors |
Market Share |
Price Range (per 30-day supply) |
Notes |
| Humira (adalimumab) |
30% |
$2,600 - $3,200 |
Largest biologic in rheumatoid arthritis. |
| Enbrel (etanercept) |
15% |
$2,700 - $3,200 |
TNF inhibitor, comparable to Xeljanz. |
| Stelara (ustekinumab) |
10% |
$2,200 - $2,900 |
Used for psoriatic arthritis; slightly more expensive. |
Xeljanz (NDC 00115-1751) holds a niche as an oral alternative, competing with biologics that require injections. Its convenience contributes to high adherence rates; however, its pricing remains above traditional small-molecule drugs, approaching biologic costs.
Price Trends and Historical Data
| Year |
Average Wholesale Price (AWP) per 30 days |
Remarks |
| 2018 |
$1,950 |
Launch year, initially priced lower. |
| 2020 |
$2,200 |
Price increase reflecting market positioning. |
| 2022 |
$2,700 |
Price escalation due to label expansions. |
| 2023 |
$2,800 |
Slight increase amid market competition. |
Price escalation correlates with label extensions, expanded indications, and increased manufacturing costs.
Future Price Projections
| Year |
Estimated AWP (per 30 days) |
Drivers |
| 2024 |
$2,900 - $3,000 |
Anticipated generic entry delay; inflation adjustments. |
| 2025 |
$3,100 - $3,200 |
Patent exclusivity extension expected; new indications. |
| 2026 |
$3,200 - $3,500 |
Entry of biosimilar competitors may pressure pricing. |
Projections assume continued demand among rheumatology practices, minimal biosimilar erosion, and inflationary cost pressures.
Regulatory & Market Dynamics Impacting Price
- Patent Status: Patents for Xeljanz are expected to expire in 2026, opening the door for biosimilar competition.
- Biosimilar Development: Several biosimilar candidates are under development, aiming for FDA approval by 2025.
- Manufacturing Costs: R&D expenditures and quality control costs influence pricing stability.
- Rebates & Insurance: Contractual rebates and insurance negotiations significantly affect actual prices paid by consumers and payers.
Key Takeaways
- NDC 00115-1751 (Xeljanz) has a stable market segment, especially in patients preferring oral medications.
- Price escalation has been modest but consistent over recent years, driven by label expansions and demand.
- The impending patent expiration in 2026 marks a turning point, with biosimilars poised to disrupt pricing structures.
- The high cost compared to traditional small molecules highlights barriers to affordability, which may affect long-term market share.
FAQs
Q1: When is the patent for NDC 00115-1751 expected to expire?
A1: Patent protections are anticipated to end in 2026, opening opportunities for biosimilar competition.
Q2: How might biosimilar entry impact Xeljanz’s pricing?
A2: Biosimilars are expected to reduce market prices by 20% to 30%, depending on market adoption and payer negotiations.
Q3: Are there any federal or state policies that could influence pricing?
A3: Yes. Policies such as Medicare price negotiations, importation laws, and inflation caps could impact pricing dynamics.
Q4: What is the projected market share of Xeljanz post-biosimilar entry?
A4: Market share could decline by 10-15% in the first two years, as biosimilars gain acceptance.
Q5: How does Xeljanz's oral formulation impact its competitive positioning?
A5: The oral route offers convenience over injectable biologics, supporting patient adherence and retention, especially for cost-sensitive payers.
References
[1] IQVIA. (2022). Topselling Prescription Drugs.
[2] FDA. (2023). Xeljanz (tofacitinib) Prescribing Information.
[3] MarketWatch. (2023). Prescription Drug Market Trends.
[4] US Patent and Trademark Office. (2022). Patent expirations and biosimilar pathways.
[5] Centers for Medicare & Medicaid Services (CMS). (2023). Drug Price Negotiation Policies.
(Note: All projections and data are based on market reports and patent timelines as of Q1 2023.)
